Cost-effectiveness of pioglitazone in patients with type2 diabetes and a history of macrovascular disease in Germany;Kosteneffektivität von Pioglitazon bei Patienten mit Typ-2-Diabetes und makrovaskulären Vorerkrankungen in Deutschland

Diabetologie und Stoffwechsel

Volumn 5, Issue 1, 2010, Pages 32-39

  Bierwirth, R ^a   Liebl, A ^b   Gschwend, M H ^c  

^a Diabetes Praxis   (Germany)

^b Fachklinik Bad Heilbrunn   (Germany)

^c IQVIA   (United States)

Author keywords

Cost effectivenes; Health economy; Pioglitazone; PROactive; Type2 diabetes

Indexed keywords

GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; SULFONYLUREA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADD ON THERAPY; ANTIHYPERTENSIVE THERAPY; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DATA BASE; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DRUG USE; GERMANY; HEALTH CARE; HEALTH CARE COST; HEALTH ECONOMICS; HEART INFARCTION; HISTORY; HUMAN; HYPOGLYCEMIA; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY ADJUSTED LIFE YEAR; RESOURCE ALLOCATION; REVIEW; RHEUMATOID ARTHRITIS; SCIENTIFIC LITERATURE; SECONDARY PREVENTION; STROKE; VASCULAR DISEASE;

EID: 77649196354     PISSN: 18619002     EISSN: 18619010     Source Type: Journal    
DOI: 10.1055/s-0029-1224723     Document Type: Review

References (50)

1. Liebl A. [Costs involved in the early and late phases of diabetes mellitus]. Internist (Berl) 2007 48 708-714
2. Liebl A, Neiss A, Spannheimer A et al. [Costs of type2 diabetes in Germany. Results of the CODE-2 study]. Dtsch Med Wochenschr 2001 126 585-589
3. Köster I, von Ferber L, Ihle P et al. The cost burden of diabetes mellitus: the evidence from Germany the CoDiM study. Diabetologia 2006 49 1498-1504
4. Köster I, Hauner H, von Ferber L. [Heterogeneity of costs of diabetic patients: the Cost of Diabetes Mellitus Study]. Dtsch Med Wochenschr 2006 131 804-810
5. Dormandy J A., Charbonnel B, Eckland D J. et al. Secondary prevention of macrovascular events in patients with type2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005 366 1279-1289
6. Scherbaum W A., Goodall G, Erny-Albrecht K M. et al. Cost-effectiveness of pioglitazone in type2 diabetes patients with a history of macrovascular disease: a German perspective. Cost Eff Resour Alloc 2009 7 9-9
7. Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004 164 2097-2104
8. Schernthaner G. Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors. Int J Clin Pract 2009 63 912-929
9. Goldberg R B., Kendall D M., Deeg M A. et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type2 diabetes and dyslipidemia. Diabetes Care 2005 28 1547-1554
10. Hanefeld M, Brunetti P, Schernthaner G H. et al. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type2 diabetes. Diabetes Care 2004 27 141-147
11. Derosa G, DAngelo A, Ragonesi P D. et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 2006 31 375-383
12. Chappuis B, Braun M, Stettler C et al. Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type2 diabetes mellitus: a prospective, randomized crossover study. Diabetes Metab Res Rev 2007 23 392-399
13. Charbonnel B, Schernthaner G, Brunetti P et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type2 diabetes. Diabetologia 2005 48 1093-1104 (Pubitemid 40909644)
14. Matthews D R., Charbonnel B H., Hanefeld M et al. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev 2005 21 167-174 (Pubitemid 40467663)
15. Schernthaner G, Matthews D R., Charbonnel B et al. Efficacy and safety of pioglitazone versus metformin in patients with type2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004 89 6068-6076
16. Deeg M A., Buse J B., Goldberg R B. et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type2 diabetes and dyslipidemia. Diabetes Care 2007 30 2458-2464
17. Langenfeld M R., Forst T, Hohberg C et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type2 diabetes mellitus: results from a controlled randomized study. Circulation 2005 111 2525-2531
18. Mazzone T, Meyer P M., Feinstein S B. et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type2 diabetes: a randomized trial. JAMA 2006 296 2572-2581
19. Nissen S E., Nicholls S J., Wolski K et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008 299 1561-1573
20. Fachinformation actos. 2009
21. Matthaei S, Bierwirth R, Fritsche A et al. Medikamentöse antihyperglykämische Therapie des Diabetes mellitus Typ2 Update der Evidenzbasierten Leitlinie der Deutschen Diabetes-Gesellschaft. http://www.deutsche-diabetes-gesellschaft.de 2008
22. Erdmann E, Dormandy J A., Charbonnel B et al. The effect of pioglitazone on recurrent myocardial infarction in 2445patients with type2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007 49 1772-1780
23. Wilcox R, Bousser M G., Betteridge D J. et al. Effects of pioglitazone in patients with type2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007 38 865-873
24. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Glitazone zur Behandlung des Diabetes mellitus Typ2. http://www.iqwig.de/download/A0505A-AB-Glitazone-zur-Behandlung-des-Diabetes- mellitus-Typ-2.pdf 2008
25. Brändle M, Goodall G, Erny-Albrecht K M. et al. Cost-effectiveness of pioglitazone in patients with type2 diabetes and a history of macrovascular disease in a Swiss setting. Swiss Med Wkly 2009 139 173-184
26. Valentine W J., Bottomley J M., Palmer A J. et al. PROactive 06: cost-effectiveness of pioglitazone in Type2 diabetes in the UK. Diabet Med 2007 24 982-1002
27. Valentine W J., Tucker D, Palmer A J. et al. Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: A US analysis based on PROactive. Value Health 2009 12 1-9
28. Palmer A J., Roze S, Valentine W J. et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004 20 Suppl 1 27-40
29. Palmer A J., Roze S, Valentine W J. et al. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004 20 Suppl1 5-26
30. Haffner S M., Alexander C M., Cook T J. et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999 159 2661-2667
31. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998 339 1349-1357
32. Goldberg R B., Mellies M J., Sacks F M. et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998 98 2513-2519
33. Ward S, Lloyd J M., Pandor A et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007 11 1-iv-1-iv
34. Zechmeister I, Wild C. Einsatz von Statinen zur Sekundärprä vention von kardiovaskulären Erkrankungen ein systematischer Review gesundheitsökonomischer Analysen. http://epub.oeaw.ac.at/ita/ita- projektberichte/ 2006
35. Obermann K, Graf von der Schulenburg J M., Mautner G C. Ökonomische Aspekte der Sekundärprävention der koronaren Herzkrankheit mit Simvastatin in Deutschland. Medizinische Klinik 1997 92 686-694
36. Johannesson M, Jonsson B, Kjekshus J et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med 1997 336 332-336
37. Cook J R., Yin D, Alemao E et al. Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: application to Germany, Spain and Norway. Pharmacoeconomics 2004 22 Suppl3 49-61
38. Kannel W B. Clinical misconceptions dispelled by epidemiological research. Circulation 1995 92 3350-3360
39. Kannel W B., Dannenberg A L., Abbott R D. Unrecognized myocardial infarction and hypertension: the Framingham Study. Am Heart J 1985 109 581-585
40. Vasan R S., Beiser A, Seshadri S et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 2002 287 1003-1010 (Pubitemid 34252058)
41. Gandjour A, Stock S. A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness. Health Policy 2007 83 257-267
42. Montgomery A A., Fahey T, Ben-Shlomo Y et al. The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis. J Hypertens 2003 21 1753-1759
43. Ekman M, Bienfait-Beuzon C, Jackson J. Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden. J Hum Hypertens 2008 22 845-855
44. Boersma C, Carides G W., Atthobari J et al. An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands. Clin Ther 2007 29 963-971
45. Palmer A J., Roze S, Rodby R A. et al. [Clinical and health economic implications of early treatment with irbesartan of patients with type2 diabetes mellitus, hypertension and nephropathy]. Dtsch Med Wochenschr 2006 131 1721-1726
46. Kielhorn A, Porter D, Diamantopoulos A et al. UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug. Curr Med Res Opin 2008 24 2639-2650
47. Chen Y F., Jobanputra P, Barton P et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006 10 iii-xiii, 1
48. Kulp W, Corzillius M, Greiner W et al. Wertigkeit von Tumor-Nekrose-Faktor-alpha-Antagonisten in der Behandlung der Rheumatoiden Arthritis. http://gripsdb-dimdi-de/de/hta/hta-berichte/hta075-bericht-de.pdf 2005
49. Eichler H G., Kong S X., Gerth W C. et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004 7 518-528
50. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004 13 437-452